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from Mutated Retroviral-Derived MTAP Transcripts
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Esteban Terzo,1 Maria Celeste Ramirez,1 Vern Schramm,2 Grace Cordovano,2 Giles Watts,3 Sarju Mehta,3
Virginia Kimonis,3 Benjamin Hoch,4 Keith D. Philibert,5 Carsten A. Raabe,6 David F. Bishop,1
Marc J. Glucksman,5 and John A. Martignetti1,7,8,*
Diaphyseal medullary stenosis with malignant fibrous histiocytoma (DMS-MFH) is an autosomal-dominant syndrome characterized by
bone dysplasia, myopathy, and bone cancer. We previously mapped the DMS-MFH tumor-suppressing-gene locus to chromosomal
region 9p21–22 but failed to identify mutations in known genes in this region. We now demonstrate that DMS-MFH results frommuta-
tions in the most proximal of three previously uncharacterized terminal exons of the gene encoding methylthioadenosine phosphor-
ylase,MTAP. Intriguingly, two of theseMTAP exons arose from early and independent retroviral-integration events in primate genomes
at least 40 million years ago, and since then, their genomic integration has gained a functional role. MTAP is a ubiquitously expressed
homotrimeric-subunit enzyme critical to polyamine metabolism and adenine and methionine salvage pathways and was believed to be
encoded as a single transcript from the eight previously described exons. Six distinct retroviral-sequence-containing MTAP isoforms,
each of which can physically interact with archetype MTAP, have been identified. The disease-causing mutations occur within one of
these retroviral-derived exons and result in exon skipping and dysregulated alternative splicing of all MTAP isoforms. Our results identify
a gene involved in the development of bone sarcoma, provide evidence of the primate-specific evolution of certain parts of an existing
gene, and demonstrate that mutations in parts of this gene can result in human disease despite its relatively recent origin.Introduction
Diaphyseal medullary stenosis with malignant fibrous
histiocytoma (DMS-MFH [MIM 112250]) is a rare, auto-
somal-dominant bone dysplasia and cancer syndrome of
unknown etiology.1–3 The disorder has a unique bone-
dysplasia phenotype characterized by cortical growth
abnormalities, including diffuse diaphyseal medullary
stenosis with overlying endosteal cortical thickening,
metaphyseal striations, and scattered infarctions within
the bone marrow. Affected individuals endure pathologic
fractures that subsequently heal poorly, progressive
wasting, bowing of the lower extremities, painful debilita-
tion, and the development of presenile cataracts. We
recently expanded the known clinical features of the
syndrome by characterizing two new unrelated families
affected by a progressive form of muscular disease consis-
tent with facioscapulohumeral muscular dystrophy
(FSHD [MIM 158900]) (see below). Among DMS-MFH-
affected individuals, approximately 35% develop a form
of bone sarcoma consistent with the diagnosis of malig-
nant fibrous histiocytoma (MFH).1–4
Using a positional-cloning approach, we originally local-
ized the disease-associated allele locus to chromosomal
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component of the syndrome, the 9p21–22 region is of
particular interest in that it is one of the most frequently
deleted and/or translocated chromosomal regions in
human cancer.5 A diverse group of human cancers
demonstrate loss of this region and include gliomas,6,7
melanomas,8 non-small-cell lung cancers,9 acute leuke-
mias,10,11 and, of direct significance to this study, osteosar-
comas.12,13 In an attempt to further narrow the region as
well as establish a link between hereditary and sporadic
tumor forms, we performed loss of heterozygosity (LOH)
analysis of sporadic MFH samples. This analysis supported
a shared genetic etiology between hereditary and sporadic
MFH cases and mapped the smallest region of overlap to
the 2.9 Mb region between markers D9S736 and
D9S171.14
A number of DMS-MFH candidate genes were originally
screened by DNA sequencing and were excluded because
they lacked mutations. These genes included the cyclin-
dependent kinase inhibitor 2A (CDKN2A [p16] [MIM
600160]) and its alternatively spliced product p14-ARF,
CDKN2B (p15), members of the interferon (IFN) super-
family, and the methylthioadenosine phosphorylase
gene (MTAP [MIM 156540]).4 MTAP has been thought
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a ubiquitously expressed enzyme that plays a crucial role
in the salvage pathway for adenine and methionine in
all tissues.16 In the salvage pathways, methylthioadeno-
sine (MTA), a by-product of the polyamine pathway, is
recovered through its phosphorolysis into adenine and
methylthioribose-1-phosphate by MTAP.17 Through a
series of reactions, methylthioribose-1-phosphate is then
converted into methionine.17,18 It is suggested that loss
of MTAP activity plays a role in human cancer because its
loss has been reported in a number of cancers, including
osteosarcoma,12,13 leukemia,19 non-small-cell lung
cancer,20 malignant melanoma,21 biliary-tract cancer,22
breast cancer,23 pancreatic cancer,24 and gastrointestinal
stromal tumors.25 Reintroduction of MTAP expression
into the MCF7 breast adenocarcinoma cell line, which
lacks endogenous MTAP gene expression and enzymatic
activity, inhibits the cells’ ability to grow both in vitro
and in vivo;23 the fact that MTAP inhibits cell growth is
consistent with its presumed role as a tumor suppressor.
We have now identified and characterized the genetic
defect underlying DMS-MFH. All affected members of
five unrelated DMS-MFH-affected families possess synony-
mous mutations in the most proximal of three terminal
MTAP exons identified and characterized in these studies.
Interestingly, DNA-sequence analysis revealed that at
least two of the exons are remnants of retroviral insertions
into the primate genome. Both disease-causing mutations
in exon 9, the most proximal of these exons, result in
exon skipping and subsequent loss of this exon in alterna-
tively spliced, biologically active isoforms. Biochemical
studies provide evidence that isoforms containing exon 7
have MTAP activity. Altogether, these findings identify
a gene associated with both hereditary bone dysplasia
and osteosarcoma and also highlight the importance of
evolutionarily co-opted gene parts for both health and
disease.Material and Methods
Linkage and Haplotype Mapping
After participants gave informed consent for these studies, which
were approved by the Human Research Protection Program at
the Mount Sinai School of Medicine, blood samples were obtained
from affected and unaffected family members. Genomic DNA was
extracted with the Puregene kit according to the manufacturer’s
(Minneapolis, MN) protocol, and individuals were genotyped
with a panel of markers spanning the length of chromosome 9;
included were markers from the Single Chromosome Scan Human
Screening Set (Research Genetics, Carlsbad, CA) and a number of
polymorphic markers that were custom generated. Family 1
from the original study was not included in this reanalysis. Allelic
determination was performed with the ABI 3130xl Genetic
Analyzer and GeneMapper 4.0 software (Applied Biosystems,
Foster City, CA). We handled the generated data by using Mega
2,26 and linkage analysis was computed by SIMWALK2 v.2.8327
with the following parameters: all families are genetically homog-
enous, inheritance pattern is autosomal dominant and has 80%
penetrance, there are no phenocopies, and the disease alleleThe Amfrequency is 0.0001. Marker positions were obtained from the
Marshfield database and the UCSC Genome Browser March 2006
assembly. We further refined areas of positive location scores by
using custom-generated microsatellite markers within the defined
region. In brief, we designed the microsatellite markers by identi-
fying simple tandem repeats (STRs) in DNA sequences of clone
fragments from the Human Genome Assembly (UCSC Genome
Browser) by using the Tandem Repeats Finder Program.28 Fluores-
cently labeled primers were then designed to amplify these repeat
regions, and allele separation and analyses were performed as
previously described29 (Table S1, available online).DNA Sequence Analysis
We used PCR to amplify all MTAP exons by using Amplitaq-Gold
(Applied Biosystems, Foster City, CA), and we purified them by
using the QIAquick Spin PCR Purification Kit (QIAGEN, Valencia,
CA); the exons were amplified and purified according to themanu-
facturers’ protocol, and they were directly sequenced on an ABI
Prism 3700 automated DNA Analyzer (Applied Biosystems, Foster
City, CA). Data were analyzed with the program Sequencher v3.0
(Gene Codes Corporation, Ann Arbor, MI). Sets of intronic primers
that we used to amplify the coding region and intron and exon
boundaries are listed in Table S1. The PCR cycling conditions
were the following: 94C (10 min) for 1 cycle, 94C (30 s), 55C
(30 s), and 72C (60 s) for 35 cycles each, and a final extension
of 72C (10 min).Computational DNA Analysis
We performed computational analysis to detect aberrant splice
sites by using the NetGene2 Server30,31 and the splicing-enhancer
motif-prediction program ESEfinder Release 2.0,32 for which we
used the default parameters for the following SR proteins: SF2/
ASF, SC35, SRp40, and SRp55.RNA Isolation, Semiquantitative Reverse
Transcription PCR, and Quantitative Real Time PCR
We extracted cultured-cell-line and tumor RNA by using the
RNeasy Mini kits, and we treated it with DNase according to the
manufacturer’s (QIAGEN, Valencia, CA) protocol. For semiquanti-
tative reverse transcription PCR (RT-PCR), we reverse transcribed
a total of 1 mg of RNA per reaction by using first-strand cDNA
synthesis with random primers (Promega, Madison, WI). To eval-
uate the transcription level of the MTAP splice variants, we per-
formed RT-PCR by using combinations of isoform-specific primers
listed in Table S1. We electrophoretically separated and visualized
RT-PCR products on a 1.5% agarose gel by using ethidium
bromide. We excised the bands and cloned and inserted them
into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA), and we
sequenced 20 independent clones from each of the isolated bands
to establish their identity. For quantitative RT-PCR (qRT-PCR), we
reverse transcribed a total of 1 mg of RNA per reaction by
using iSCRIPT cDNA Synthesis according to the manufacturer’s
(Bio-Rad, Hercules, CA) protocol. We performed qRT-PCR by using
iQ SYBR Green Supermix (Bio-Rad, Hercules, CA), according to the
manufacturer’s protocol, on an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA) and by
using the primers listed in Table S1. All values were normalized
to either GAPDH or HPRT levels. All experiments were done in
triplicate, and all cell-culture experiments were independently
validated at least three times.erican Journal of Human Genetics 90, 614–627, April 6, 2012 615
RACE: Rapid Amplification of cDNA 30 Ends
Total RNA was isolated from five primary human fibroblast cell
lines. We used a total of 1 mg of RNA per cell line, the PowerScript
Reverse Transcriptase, and the BD SMART IIA primer from the BD
SMART RACE cDNA amplification kit (according to the manufac-
turer’s [Franklin Lakes, NJ] protocol) to prepare corresponding
first-strand cDNAs. In brief, each of the 30 RACE-ready cDNAs
was used in PCR-amplification reactions with the SMART RACE
kit universal primers and sense gene-specific primers (GSP). First-
round PCR and second-round PCR were performed with the
specific primers listed in Table S1, Outer Primer (SMART RACE
kit), and Inner Primer (SMART RACE kit).Cell Culture and Transfections
Patient-derived osteosarcoma, fibroblast, and lymphoblast cell
lines and other commercially available cell lines (obtained from
ATCC) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin and were grown at 37C
in 5% CO2. For the expression studies, we transfected the cells
24 hr after plating by using lipofectamine 2000 according to
the manufacturer’s (Invitrogen, Carlsbad, CA) recommended
protocol.Expression Constructs
GST and V5 Expression Vectors
To generate the vectors expressing each of the MTAP splice
variants (archetype MTAP and MTAP_v1, _v2, _v3, _v4, _v5,
and _v6), we used RT-PCR to amplify the cDNA of each splice
variant from normal fibroblasts by using the relevant primers
listed in Table S1. In brief, the exon 1 forward primer was used
for the amplification of all variants, and the reverse primers were
designed to delete the stop codon so that a fusion protein would
be generated with the V5 epitope. The amplified products were
cloned and inserted into the pcDNA3.1/V5-His TOPO TA expres-
sion vector (Invitrogen, Carlsbad, CA). The resulting clones were
completely sequenced in both orientations prior to their use.
Partial Minigene Expression Vectors
We used genomic DNAs obtained from a normal fibroblast cell line
and two patient-derived fibroblast cell lines to amplify the
following fragments: an 8 kb fragment containing exons 6–8
(flanked by introduced SalI and NheI restriction sites; subcloned
into the pcDNA3.1/V5-His TOPO TA vector), 2.1 kb fragments
containing exon 9 and carrying the wild-type (WT) DNA or either
the c.813-2A>G or c.885A>G mutation (flanked by introduced
SpeI and XhoI restriction sites; cloned into the pCR4-TOPO
vector), and a 3 kb fragment containing exons 10 and 11 (flanked
by introduced XhoI and SacII restriction sites; cloned into the
pCR4-TOPO vector). Each 2.1 kb fragment was digested with
SpeI and XhoI, and we cloned the fragments and inserted them
into a SpeI/XhoI-digested pcDNA3.1 (exons 6–8) vector to
generate the following three pcDNA3.1 (exons 6–8 and 9)
constructs:WT, c.813-2A>G, and c.885A>G. Finally, the 3 kb frag-
ment was digested with XhoI and SacII and cloned and inserted
into each one of the three pcDNA3.1 (exons 6–8 and 9) vectors di-
gested with XhoI and SacII. The following three pcDNA3.1 (exons
6–8 and 9–11) minigene expression vectors were created: WT,
c.813-2A>G, and c.885A>G. The primers that we used are listed
in Table S1. We performed PCR amplifications by using the
EXPAND Long Template PCR system according to the manufac-
turer’s (Roche, Indianapolis, IN) protocol. We sequenced all exons616 The American Journal of Human Genetics 90, 614–627, April 6, 2and approximately 500 base pairs of the intron-exon flanking
boundaries of the generated plasmids.
Coimmunoprecipitation Assay
Relevant combinations of GST- and V5-tagged constructs for
archetype MTAP and MTAP_v1, _v2, _v3, _v4, _v5, and _v6 were
cotransfected into PC3M cells. All of the following procedures
were performed at 4C. Cell extracts for immunoblotting were har-
vested in NP40 lysis buffer (Santa Cruz Biotechnology, standard
protocol), and insoluble material was removed by centrifugation
(10 min at 13,000 rpm). One tenth of the cell extracts were
reserved for subsequent immunoblot analysis. Cell extracts were
incubated with V5 antibody (1 mg/ml) or GST antibody (1 mg/ml)
for 4 hr and Protein A-Sepharose (Invitrogen, Carlsbad, CA). Beads
were washed three times with 1% lysis buffer, and coimmunopre-
cipitates were released by being boiled in 100 ml 23 SDS Reducing
Sample Buffer (Invitrogen, Carlsbad, CA) for 5 min. Coimmuno-
precipitates were analyzed by immunoblot analysis (see below).
Immunoblot and Densitometric Analysis
Cell extracts for immunoblotting were harvested in radioimmuno-
precipitation assay (RIPA) buffer (Santa Cruz Biotechnology,
standard protocol). Equal amounts of protein (50 mg) as deter-
mined by the BioRad DC Protein quantification assay were loaded
and separated by polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes. We performed immunoblot-
ting by using a goat polyclonal antibody to actin (SC-1615), a
monoclonal (0.2 mg/ml) antibody to GST (BD PharMingen), and
a monoclonal antibody to the V5 tag (Santa Cruz Biotechnology).
We analyzed enhanced chemiluminescent images of immuno-
blots by using a scanning densitometer and quantifying the bands
(BIOQUANT NOVA imaging system). All values were normalized
to actin and expressed as fold changes relative to the control.
MTA Quantification
Blood-serum and cell-extract lysates were mixed with 63 pmol
[50-2H3] MTA, neutralized with KOH, and centrifuged. MTA frac-
tions were purified by HPLC (SymmetryShield RP18 column),
concentrated, dissolved in 10% methanol with 0.1% TFA, and
subjected to LCQ ESI-MS analysis. MTA was quantitated with an
internal mass standard of [50-2H3] (301 amu) relative to the peak
area for authentic MTA (298 amu). Samples were analyzed in
triplicate.
MTAP Enzymatic Activity Assay
Cells were trypsinized and washed twice with PBS, and the cell
pellets were frozen at80C. On the day of the analysis, the pellets
were thawed on ice and resuspended in MTAP lysis buffer (20 mM
potassium phosphate, pH 7.4, 1 mM dithiothreitol, and Roche
complete, EDTA-free protease cocktail in a dilution equivalent to
1 tablet for 125 ml of lysate buffer), sonicated three times for
15 s each and cooled on ice between sonications, and centrifuged
at 13,000 3 g for 15 min at 4C. Protein concentrations were
measured with the Bio-Rad DC Protein Assay. The MTAP-activity
assay was as described33 and had the following modifications:
Cell lysates or an enzyme blank consisting of an equal volume
of lysis buffer was preincubated at 37C for 5 min in 86 ml of a
solution containing 116 mM potassium phosphate, 58 mM KCl,
and 0.23 mM dithiothreitol in quartz microcuvettes. The enzyme
reactions were started with the addition of 4 ml xanthine oxidase
(0.15 units) and 10 ml of 5 mM MTA. Data was collected for012
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Figure 1. Pedigrees of the Five DMS-MFH-Affected Families
Families 1, 2, and 3 were originally described as the ‘‘American,’’ ‘‘Australian,’’ and ‘‘New York’’ families, respectively.1–3 Family 4 is
a previously undescribed DMS-MFH-affected family from New York. Family 5 has been described as having autosomal-dominant
bone fragility and limb-girdle myopathy.34 Family members classified as ‘‘suspected by history’’ were unavailable for radiological diag-
nosis but had a history of multiple (>2) pathological fractures and/or had children whowere clinically diagnosed with DMS-MFH on the
basis of plain-film X-rays and family history.1,300 s, and the rates were calculated by a linear fit to the data
between 800 and 1,100 s. The blank rate was subtracted from all
the enzyme rates. MTAP-assay rates were linear; the lysate protein
concentration ranged from 10 to 500 ng protein per assay. One
unit of MTAP activity is the amount of enzyme that catalyzed
the formation of 1 mmole of adenine per minute under the condi-
tions of the assay.Results
Positional Cloning of the DMS-MFH-Associated Gene
Previously, we performed genome-wide linkage analysis
and haplotype reconstruction on three unrelated families
to establish the critical region of the DMS-MFH-associated
gene as a 3.5 cM locus in chromosomal region 9p21–22.
The centromeric boundary was defined by D9S1778, and
the telomeric end was defined by D9S171.4 Since the
original mapping, we identified two additional families
(families 4 and 5) (Figure 1). Interestingly, both of the
new families had evidence of a progressive myopathicThe Amdisease (Martignetti et al., unpublished observations34)
not previously noted in the three original families. The
disease-associated gene for one of these later multigenera-
tional families (this family was originally described by
Henry et al.35 as having a history of bone disease, patho-
logic fractures, fibrosarcoma, cataracts, and myopathy
(MIM 609940]) had been independently mapped to a
15 Mb region at 9p21–22.34 This region broadly overlap-
ped the DMS-MFH critical region. To determine whether
these two additional families affected by myopathic
disease were allelic and supported the previously identified
DMS-MFH critical region, we performed multipoint
parametric linkage analysis by using markers spanning
chromosome 9.
We analyzed all five families by using a combination of
previously described and laboratory-developed microsatel-
lite markers. A maximal combined location score of 4.27
was obtained for marker D9SB3 (Figure 2A). We then per-
formed haplotype analysis of additional markers within
the shared region and reconstruction of haplotypes toerican Journal of Human Genetics 90, 614–627, April 6, 2012 617
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Figure 2. Identification of the Critical Region and the DMS-MFH-Associated Gene
(A) The results of a combined multipoint parametric linkage analysis for families 2, 3, and 4. The maximal location score is 4.27 at
marker D9SB3.
(B) Haplotype analysis of informative individuals from families 2, 3, and 4 narrowed the DMS-MFH critical region (boxed).
(C) Physical map of the DMS-MFH critical region, which spans 1.3Mb between the flankingmarkers AL882 and D9S976. Arrows indicate
transcriptional direction of candidate genes. The exon-intron structure of MTAP highlights the eight exons of MTAP (green) and the
three terminal exons (blue). Maps are not drawn to scale.
(D) Representative DNA-sequence chromatograms from selected affected and unaffected individuals from each family.
(E) Tumor DNA sequence revealing homozygosity of the diseased allele and loss of the unaffected allele.further narrow the region. The minimal disease locus was
established by recombination events between markers
AL882 and D9S1749 in unaffected individual F3 IV-6 and
between markers D9S916 and D9S976 in affected indi-
vidual F3 IV-7. These events narrowed the critical region
to 1.2 Mb (Figure 2B).
DNA-sequence analysis of known candidate genes
within the original critical region had previously failed to
identify causative mutations.4 In particular, this analysis
included the known eight exons and corresponding
intron-exon boundaries of MTAP.4 Having exhausted all
known genes, we next sought and analyzed predicted
genes and putative open reading frames (ORF) from within
the region. In silico analysis of the region with the use of618 The American Journal of Human Genetics 90, 614–627, April 6, 2the UCSC Genome Browser identified an ORF (GenBank
accession number AF216650) located 65 Kb downstream
of the known MTAP termination site within a truncated
expressed sequence tag (EST). DNA-sequence analysis of
the putative 192 bp ORF, which we termed MTAP exon 9,
and its intron-exon boundaries revealed the presence of
one of two heterozygous A>G substitutions for all affected
members of the first four DMS-MFH-affected families
(Figure 2D). Using the EST clone (GenBank accession
number AK309365) as a reference, we determined that
one mutation was a synonymous change at position
c.885A>G (p.(¼)), effectively R100R, and was present in
affected families 1, 3, and 4. The second mutation, c.813-
2A>G, was an intronic change present in affected family012
Figure 3. Histopathological Analysis of an Osteosarcoma from
Patient F4 IV-2
(A) Histologic analysis revealed that 95% of the studied tumor
specimen displayed the typical pattern of malignant spindle
(fibroblastic) cells of bone MFH.
(B) Malignant cells forming neoplastic bone.
(C) Focal sheets of neoplastic bone within the tumor are shown to
be entrapping pre-existing bone trabeculae, and the overtly malig-
nant cells are shown to produce bone. All sections were stained
with hematoxylin and eosin.2. The sequence changes segregated appropriately with
the disease phenotype within all respective family
members in each family. We then analyzed affected and
unaffected individuals from family 5; all affected individ-
uals possessed the c.813-2A>Gmutation. To test the possi-
bility that these changes represented polymorphisms and
not pathogenic mutations, we screened a control popula-
tion. Neither mutation was identified in 1,000 chromo-
somes from 500 unaffected control individuals. Similarly,
the mutations were not present in dbSNP build 131.
The DMS-MFH Mutation Is Homozygously Present
in a Patient-Derived Osteosarcoma
MFH is a rare, highly aggressive bone tumor of uncertain
histogenesis but whose histologic appearance, treatment,
and response are similar to those of osteosarcoma.36,37
Indeed, the diagnosis of MFH has been controversial, and
in cases where osteoid is present, the diagnosis of osteosar-
coma is favored.38 Approximately one-third of affected
individuals within our families developed bone sarcomas
arising between the second and fifth decades of life. The
diagnoses were either MFH3 or bone fibrosarcoma.1 As
shown in Figure 3, given the presence of osteoid, the histo-
pathological analysis of a tumor from a DMS-MFH-affected
individual (III-3 from family 4; c.885A>G) is consistent
with the diagnosis of osteosarcoma. Thus, inherited
MTAP alternative-splicing mutations can result in
histology-proven osteosarcoma.
Moreover, and in agreement with Knudson’s two-hit
hypothesis for a tumor-suppressing gene,39 direct
sequencing of this patient’s osteosarcoma genomic DNA
demonstrated homozygosity for the c.885A>G mutation
(Figure 2E). LOH analysis withmicrosatellite markers span-
ning the originally defined 2.9 Mb DMS-MFH critical
region revealed complete loss of the WT allele from the
unaffected chromosome (data not shown).
DMS-MFH Mutations Result in Exon Skipping and
Altered Expression of MTAP Isoforms
Given the identification of these disease-specific genomic
DNA mutations, we sought to understand the relationship
between the previously uncharacterized ninth exon and
the MTAP RNA transcripts. Therefore, we performed 30
RACE on the total RNA isolated from control and patient-
derived fibroblast and lymphoblast cell lines and also
from a patient-derived tumor cell line that we established.
For 30 RACE, we used intron-spanning primers anchored
in exons 5 and 6 of the WT gene and sequenced the result-
ing cDNA products. Using this approach, we identified, as
expected, the archetype MTAP transcript and, in accord
with our hypothesis, additional isoforms containing exon
9. In total, six additional isoforms were identified; none
contained the WT terminal exon 8, and all affected the C
terminus of the protein product in different ways
(Figure S1). Four contained either a short (9S; 103 nt) or
long (9L; 192 nt) form of exon 9. Additionally, four of the
isoforms contained a unique sequence that was mappableThe Amto two additional downstream exons, 10 and 11 (Figure 2C
and Figure S1). On the basis of the electrophoretic mobility
of the MTAP transcripts generated, we named the six alter-
native splice variants MTAP_v1 (exons 1–7 and 9S–11),
_v2 (exons 1–7 and 9L), _v3 (exons 1–7, 10, and 11), _v4
(exons 1–6 and 9S–11), _v5 (exons 1–6 and 9L), and _v6
(exons 1–6, 10, and 11). Splice variants 1–3 contained the
WT exon 7 sequence; variants 4–6 did not.
The two DMS-MFH mutations, one intronic and the
other exonic, did not predict amino acid changes. We
hypothesized that one possible pathogenic mechanism
could be through an effect on alternative splicing. We
analyzed the DNA sequence for the presence of knownerican Journal of Human Genetics 90, 614–627, April 6, 2012 619
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Figure 4. Patient-Derived MTAP Mutations Result in Exon Skipping
(A) Sequence differences of the three minigene constructs, WT, c.813-2A>G, and c.885A>G, are highlighted.
(B) Schematic representation of the major sequence-verified isoforms flanking the electrophoretic profile of each minigene construct.
Arrowheads above exons depict the positions of translational stop codons. The WT construct expresses all alternative splice variants
that are detectable with this combination of primers (exon 6 forward [Ex6F] and exon 11 reverse [Ex11R]) (left), whereas patient-derived
mutant constructs, c.813-2A>G and c.885A>G, expressed relatively very low levels of exon-9S- and -9L-containing variants, v1/v4 and
v2/v5, respectively. By comparison, the expression of isoforms v3 and v6 was markedly elevated in both mutant constructs.
(C) qRT-PCR analysis of archetype MTAP and isoform expression in cells that express each of the minigene constructs. Expression anal-
ysis of the three minigene constructs demonstrated that the c.813-2A>Gmutant construct resulted in significantly increased archetype
MTAP expression levels, whereas both the c.813-2A>G and c.885A>G mutant constructs were associated with an absence of and/or
significantly decreased levels of MTAP_v1, _v2, _v4, and _v5. Bothmutant constructs resulted in significantly increased expression levels
of MTAP_v3 and _v6. The following abbreviation is used: wtMTAP, archetype MTAP. The error bars represent the averages of three inde-
pendent experiments.donor and acceptor splice motifs and intronic and exonic
cis elements that could direct splice-site identification.
The intronic c.813-2A>Gmutation was predicted to result
in the loss of a canonical splice acceptor site.31 The
c.885A>G transition abolished a predicted exonic splicing
enhancer (ESE) sequence.32
To validate these in silico findings, we generated
three MTAP minigene constructs, WT, c.813-2A>G, and
c.885A>G, containing ~11.5 Kb of genomic sequence620 The American Journal of Human Genetics 90, 614–627, April 6, 2and differing at only the single nucleotide position being
interrogated (Figure 4A). The minigene constructs were
transiently transfected into MCF7 cells, and the relative
expression levels of each isoform were determined by
qRT-PCR. The identity of each transcript was established
by RT-PCR, subcloning, and the sequencing of at least 20
independent clones from gel-isolated bands.
The three differentMTAP constructs revealed clear differ-
ences in the expression pattern of splice variants, whereas012
Figure 5. Dysregulated MTAP Splicing Patterns in Patient-Derived Cell Lines
MTAP expression patterns in patient-derived and control fibroblast (A) and lymphoblast (B) cell lines. Semiquantitative RT-PCR analysis
is on the left, and qRT-PCR analysis of archetype MTAP is on the right.
(A) C1, C2, C3, and C4 are controls. Fibroblast and tumor cell lines are from affected individual F4 III-3.
(B) C1 and C2 are controls. Lymphoblast cell lines are from individuals F3 IV-5, F3 IV-6, F3 IV-7, F4 III-5, and F4 III-6. The following
abbreviation is used: wtMTAP, archetype MTAP.expression of the WT form was unchanged (Figure 4B).
Although the WT gene construct directed expression of all
seven MTAP transcripts, the single-nucleotide changes at
c.813-2A>G and c.885A>G resulted in markedly decreased
expression of the four exon-9-containing transcripts,
namely MTAP_v1, _v2, _v4, and _v5. In contrast, there
was a significant increase in the two isoforms lacking exon
9, namely MTAP_v3 and _v6. Differences were noted in
the transcription effects of the two mutations. Quantifica-
tion of the resultant isoforms by qRT-PCR demonstrated
that the c.813-2A>G mutation ablated expression of all
isoforms containing exon 9 and significantly increased the
expression of archetype MTAP (Figure 4C). In addition, the
first three amino acids were lacking from both 9S isoforms.
The c.885A>G mutation decreased the expression levels
of all exon 9 isoforms by approximately 70% but had no
effect on archetype-MTAP expression. Both patient-derived
mutations significantly increased the expression of
MTAP_v3 and _v6 to the same degree (Figure 4C).
The mutation-dependent isoform expression pattern
that we identified by using the engineered minigeneThe Amexpression constructs was also present in patient-derived
tissues. As shown in Figure 5, patient-derived fibroblast
and lymphoblast cell lines, constitutively heterozygous
for the mutations, demonstrated MTAP isoform expression
patterns similar to each other but markedly different from
the expression patterns of control cells (Figures 5A and 5B).
Quantitative RT-PCR analysis revealed that in patient-
derived cells, expression levels of MTAP_v1 and expression
levels of MTAP_v3 and _v6 were approximately 50% lower
and nearly five to ten times higher, respectively, than those
of the controls (Figures 5A and 5B). In both these cell-line
types, we were unable to consistently detect quantifiable
levels of MTAP_v2, _v4, and _v5 (results not shown).
MTAP Splice Variants Can Physically Interact with
Archetype MTAP and Are Biologically Active
We began exploring the function of the different MTAP
splice variants by first determining their respective protein
stabilities. The transient transfection of expression vectors
(which contained each isoform fused with a 30 V5 and/or
a 50 GST terminal tag) into MCF7 cells demonstrated thaterican Journal of Human Genetics 90, 614–627, April 6, 2012 621
Table 1. MTA Serum Levels
Serum Donor MTA Level (pmol/100 ul)
F4 III-1 11.5
F4 IV-2 4.3
F4 IV-3 not detected
Control 1 not detected
Control 2 not detectedall six MTAP splice variants were translated. Although RNA
levels were essentially equivalent (data not shown), there
was, however, a large variability in protein expression
levels (Figure S2). Archetype-MTAP and MTAP_v1, _v2,
and _v3 proteins (i.e., those containing exon 7) were
expressed at comparable levels, whereas MTAP_v4, _v5,
and _v6 were expressed at markedly lower levels.
These findings suggest a possible difference in protein
stability that might be regulated through the proteosome
pathway. To test this hypothesis, we treated the transfected
cells with the proteosome inhibitor MG132. The v4, v5,
and v6 isoforms accumulated, whereas archetype MTAP
and variants v1, v2, and v3 were relatively unaffected
(Figure S2A). The half-life of each splice variant was esti-
mated by cyclohexamide treatment. The half-life of arche-
type MTAP and MTAP_v1, _v2, and _v3 wasR12 hr. It was
significantly less than 6 hr for MTAP_v4, _v5, and _v6
(Figure S2B).
Given these findings and the knowledge that MTAP
exists as a trimeric40–42 protein complex, we tested the
ability of the MTAP splice variants to physically interact
with archetype MTAP. We performed coimmuprecipita-
tions on cell extracts from cotransfected PC3M cells by
using combinations of V5- andGST-tagged fusion proteins.
All MTAP splice variants were able to physically interact
with archetype MTAP (Figure S3).
We next sought to determine whether MTAP splice vari-
ants have MTAP activity. We directly measured the ability
of each isoform to convert MTA to adenine by using a
biochemical assay after we stably transfected them into
two MTAP-null cell lines, MCF7 and MNNG-HOS (a
human-osteosarcoma-derived cell line). Cellular lysates
from mock-transfected cells demonstrated negligible
MTAP activity. Against this null-activity background,
only MTAP isoforms v1, v2, and v3 demonstrated MTAP
activity (Figure S4). Given that variants v4, v5, and v6
had appreciably shorter half-lives, we also performed these
studies in the presence of MG132. Despite the presence of
these isoforms, as determined by immunoblot analysis, we
were unable to detect MTAP activity within the limits of
our assay system (data not shown).
MTA Serum Levels Are Increased in DMS-MFH
MTA is not normally present in human serum. Cells lack-
ing MTAP activity are unable to metabolize MTA,43 and622 The American Journal of Human Genetics 90, 614–627, April 6, 2functional inhibition44 or dysregulation of MTAP activity
would therefore be expected to result in intracellular MTA
accumulation and secretion. When tumor cells are MTAP
deficient, excess MTA would be expected to be cleared by
surrounding MTAP-normal stromal cells. If MTAP expres-
sion or activity is globally affected in all tissues, for
example, in an individual with an inherited germline
MTAP deficiency, then serum levels of MTA should be
increased. To establish whether decreased expression of
exon-9-containing isoforms affects MTAP activity, we
measured MTA serum levels in DMS-MFH-affected family
members and controls. Serum samples from two affected
adults (F4 III-1 and F4 IV-1), one unaffected familymember
(F4 IV-3), and two unrelated controls were analyzed in a
blinded fashion. All three serum samples from unaffected
individuals had no detectable MTA levels. In marked
contrast, both affected individuals had accumulations of
MTA detectable in their serum (Table 1).
Molecular Modeling of MTAP Isoforms
The high-resolution structure of human archetype MTAP
has been previously determined by X-ray crystallography
with several ligands. Most relevant is the trimeric enzyme
complex including 50-deoxy-50-methylthioadenosine sul-
fate (PDB ID 1CG6) and the MTAP apoprotein (PDB ID
1CB0).36 These structures of human 50-deoxy-50-methyl-
thioadenosine phosphorylase at 1.7 A˚ resolution provide
insights into substrate binding (Figure 6A) and catalysis
and serve as a template for modeling potential interactions
among the subunits. On the basis of this model, the amino
acid sequences providing the substrate binding site are en-
coded primarily by exons 6 and 7. Only the L279 residue is
provided by exon 8 (Figure S5). The structure reveals that
each of the three identical subunits is comprised of an
alpha-beta domain containing an eight-stranded and a
five-stranded mixed beta sheet with six dispersed alpha
helices similar to the family of purine nucleoside phos-
phorylases (Figure 6B). On the basis of the results of our
coimmunoprecipitation experiments, the MTAP trimer
could exist as a heterologous assembly of different subunits
comprised of archetype and splice variants. In the MTAP
splice variants, the 75 amino acids of v1 are inserted after
K271, and those of v4 are inserted after A230. In the
MTAP monomer, v1–v3 and v4–v6 oppose each other,
but most importantly, at the interfaces of different sub-
units of the trimer, all of the splice variants are relatively
close to each other spatially, regardless of in which exon
amino acids are inserted within the symmetrically equiva-
lent subunits. As seen in Figure 6C, exon 6 is in juxtaposi-
tion with exon 7 of the adjacent subunit. The trimeric
subunit interface of MTAP does appear to be affected by
the alternate splicing events or, possibly, the MTA active
site (Figure 6C). Secondary-structure and disulfide-bond
prediction analyses predict the generation of a disulfide
bond between cysteine residues in exons 9 and 10; these
prediction analyses require future biochemical analysis
for validation.012
Figure 6. Molecular Modeling of MTAP
Modeling is based on the coordinates of the trimeric enzyme complex including 50-deoxy-50-methylthioadenosine sulfate (PDB ID
1CG6) and the MTAP apoprotein (PDB ID 1CB0).42 Rendering was done with the program O v.13 (courtesy of Dr. Alwyn Jones, Univer-
sity of Uppsala, Uppsala, Sweden), and visualization was done with the PyMOL molecular graphics system v.1.3 (Delano Scientific).
(A) Overview of the top of the MTAP trimer. The stick representation (arrow) indicates the MTA substrate.
(B) View of an MTAP monomer. The insertion positions of exon 7 (salmon) and exon 6 (tan) are at opposite ends.
(C) View of the bottom of the MTAP trimer. Subunits and the insertion positions of exon 7 (salmon) and exon 6 (tan; discontinuous
electron density) are indicated. Displayed is the close proximity of one of these junctions: exon 7 in subunit 2 with exon 8 in subunit
3. Because of the three-fold symmetry, there is the possibility of three splice-variant insertion points in the trimer.Ancestral Retroposition Events Gave Rise to Specific
MTAP Exons in Humans and Possibly Other
Anthropoid Primates
Sequence analysis of the three terminal exons revealed that
exons 9 and 10 shared high homology with different
primate-specific retroviral sequences, which are known to
have integratedmultiple times into different chromosomes
throughout the genome. In general, human endogenous
retrovirus (HERV) sequences are the result of ancestral infec-
tion events that can become incorporated into the genome
and transmitted vertically through speciation events.45 As
shown in Figure 7A, an analysis (with the use of programs
RepeatMasker andRetrosearch) of exons 9 and10 suggested
that these exons arose from integrated retroviruses from
distinct subfamilies. Exon 9 arose from part of a MER50I
element, and exon 10 arose from part of a THE1A element,
one of several families of primate-specific long terminal
repeat (LTR) retrotransposons.46 Both the c.813-2A>G
and c.885A>Gmutations in exon 9 represent G>A nucleo-
tide transitions from the consensus MER50I sequence.
To more precisely establish the evolutionary age of exon
9, which contains the DMS-MFH mutations, we amplified
and sequenced this exon and its intron-exon boundaries
from a panel of primate genomic DNA. PCR amplicons
were obtained and sequenced for confirmation in great
apes and Old and New World monkeys. No product was
amplified from the ring-tailed lemur, a member of an
ancestral extant primate lineage (Figure 7). From this
analysis, we could determine that the MER50I remnant,
which now encodes MTAP exon 9, was integrated over
40 million years ago into the lineage leading to anthropoid
primates.The AmDiscussion
Hereditary cancer syndromes represent a powerful and
tractable biologic system for identifying cancer-causing
mutations.47 Although the syndromes themselves are
rare, their study can provide insight into the basis of the
sporadic forms of the cancers. DMS-MFH represents the
only known hereditary form of MFH, which has been
thought to exist along a spectrum of bone sarcomas with
osteosarcoma. Osteosarcoma itself has been linked to
several hereditary disorders, including Li-Fraumeni
syndrome (MIM 151623), Rothmund-Thomson syndrome
(MIM 268400), Bloom syndrome (MIM 210900), Werner
syndrome (MIM 277700), Paget disease (MIM 602080),
and retinoblastoma, albeit the incidence of cancer devel-
opment associated with these syndromes is lower when
compared to the >30% associated with DMS-MFH.
Recently, one of our affected individuals developed histo-
logically proven osteosarcoma (Figure 3), thus further sup-
porting a genetic link between these tumor types.
The 9p21 region containing theMTAP locus is one of the
most frequently deleted and/or translocated chromosomal
regions in human cancer.5 The facts that MTAP is more
complex than previously recognized and that its terminal
coding exon lies within 25 kb of the p15/p16 locus has
immediate significance to LOHmapping and copy number
variation (CNV) studies in human cancer. Deletions
including the p15/p16 locus will more than likely also
include the 30 region of MTAP and therefore might
affect MTAP biochemical activity. Thus, the interpretation
of many of these studies with regard to the genes
being affected should be reevaluated. Ultimately, theerican Journal of Human Genetics 90, 614–627, April 6, 2012 623
Figure 7. Evolution of MTAP Exon 9
(A) Schematic representation demonstrating that exons 9 and 10 arose from distinct families of retroviral integration events.
(B) The PCR results of exon 9 in a primate genomic DNA panel are superimposed adjacent to a phylogenetic tree. The results demonstrate
that exon 9 was integrated into the primate genome at some point in evolution between the divergence of the ring-tailed lemur and the
common woolly monkey approximately 40 million years ago.identification of the MTAP splice variants and the fact that
their genetic loss results in DMS-MFH provide a possible
in vivo demonstration that MTAP can act as a tumor
suppressor. Given our findings that the DMS-MFH muta-
tions also result in overexpression of two splice variants,
MTAP_v3 and _v6, the possibility that at least two of the
MTAP isoforms could represent oncogenic variants must
also be considered at this time.
Of possible related significance, the 9p21 chromosomal
region containing the full-length MTAP has been linked
to coronary artery disease (CAD [MIM 611139]) and
myocardial infarction in three independent genome-wide
association studies (GWASs).48–50 Because of a paucity of
known transcripts in the linkage-disequilibrium block,
the region has been viewed as a ‘‘gene desert.’’MTAPmight
represent an intriguing heart-disease candidate gene for
several reasons. First, in DMS-MFH-affected family 1, two
male family members died of heart disease in their early
forties without other known risk factors. A third family
member has been recently diagnosed with early CAD
(J.A.M., unpublished data). As such, CAD might represent
a previously unrecognized aspect of the disease phenotype
in this syndrome. Second, two of our families have been
diagnosed with myopathic disease and have features over-
lapping the symptoms of facioscapulohumeral muscular
dystrophy and limb-girdle muscular dystrophy. Each of
these chronic myopathic disorders is associated with an624 The American Journal of Human Genetics 90, 614–627, April 6, 2increased risk of heart disease.51,52 Third, defects in poly-
amine metabolism have been associated with defects in
angiogenesis53 and altered myocyte function,54,55 whereas
a nearly pathognomonic feature of DMS-MFH bone
dysplasia is the presence of scattered infarctions through-
out the medullary cavity.4 Finally, the CAD risk alleles
identified in the original GWASs have been shown to
localize to a STAT1-dependent enhancer element that can
interact with MTAP and affect its transcription.56 Future
studies will be required for exploring the possible role(s)
of MTAP in CAD.
An intriguing evolutionary aspect of these studies is the
origin of the three terminal MTAP exons. Mammalian
chromosomes are interspersed with remnants of ancient
retroviral integration events. It is estimated that 8% of
the human genome consists of retroelements containing
LTRs that flank regions corresponding to the gag, pol, and
env genes.57 Although they usually infect somatic cells,
retroviruses can also infect germ cells and establish perma-
nent residence and future vertical transmission through
a species in a Mendelian fashion.46 Indeed, the majority
of HERVs are present in apes and Old World monkeys,
suggesting that their original integrations took place
more than 25 million years ago,58 and evidence now
exists that some HERV proteins have been co-opted into
functional roles.59 Two of the clearest examples are
provided by the expression of two fusogenic proteins by012
trophoblasts. Syncytin 1 had been derived from a HERV-W
envelope glycoprotein, is expressed in all trophoblastic
cells, and mediates trophoblast cell fusion into the multi-
nucleated syncytiotrophoblast layer. Syncytin 2, derived
from a HERV-FRD envelope glycoprotein, is expressed in
human placenta.60–62 Our studies reveal that two of the
three terminal exons of MTAP are derived from indepen-
dent retroviral integration events during primate evolu-
tion. Although the integration of exon-9-associated
material most likely occurred after prosimian and New
World monkey divergence more than 40 million years
ago (Figure 7), the timing of its being functionally co-opted
is presently unknown.
The retroviral origins of the terminal exons of MTAP
suggest a number of interesting a priori conclusions. First,
given the evolutionary species restriction of these HERVs,
the existence of MTAP variants and possible biochemical
regulation resulting from their expression must be unique
to primates. Second, the exon 9 mutations that result in
DMS-MFH highlight not only the existence of MTAP
isoforms but also that their heterozygous loss (v1, v2, v4,
and v5) and/or overexpression (v3 and v6) results in
disease. This functionally demonstrates the importance
of the acquired domains in MTAP function and their fixa-
tion into normal human physiology. This phenomenon,
the recruitment and fixation over evolutionary time of a
nucleic-acid sequence as a functional gene, or part thereof,
is termed exaptation, and a number of examples are
known.63–65 However, we are unaware of any other
example wherein the loss of a co-opted gene and/or
protein domain results in a disease phenotype.
Finally, our results continue to demonstrate the dynamic
nature of the genome and the dual reality of disease asso-
ciations and beneficial implications for both alternative
splicing and retroelements. Future studies will now be
required for defining the exact biochemical function(s)
and regulation of these isoforms, their association with
bone dysplasia, cancer initiation, and CAD, and their inter-
action with archetype MTAP.Supplemental Data
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